2011 - 2012 A basic studyon malignant mesothelioma pathogenesis by internal radiation exposure of radium contained in the iron-containing protein
2007 - 2008 Chemoprevention of Lung Cancer using Epidermal Growth Factor Receptor Transgenic Mice
Show all
Papers (168):
Hiroaki Matsuura, Go Makimoto, Naohiro Oda, Kiichiro Ninomiya, Hisao Higo, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, et al. A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing. Internal medicine (Tokyo, Japan). 2024. 63. 19. 2655-2660
Kiyotaka Yoh, Koichi Azuma, Hidetoshi Hayashi, Makoto Nishio, Kenichi Chikamori, Eiki Ichihara, Yasutaka Watanabe, Takayuki Asato, Tadayuki Kitagawa, Robert J Fram, et al. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. International journal of clinical oncology. 2024. 29. 10. 1461-1474
Noriko Miyake, Nobuaki Ochi, Masami Takeyama, Hideko Isozaki, Eiki Ichihara, Hiromichi Yamane, Takuya Fukazawa, Yasunari Nagasaki, Tatsuyuki Kawahara, Hidekazu Nakanishi, et al. A novel molecular target, superoxide dismutase 1, in ALK inhibitor-resistant lung cancer cells, detected through proteomic analysis. Experimental cell research. 2024. 442. 2. 114266-114266
Taichi Ozeki, Hisao Higo, Hiroki Omori, Shunta Mori, Shin Tanaka, Go Makimoto, Kiichiro Ninomiya, Akihiko Taniguchi, Masanori Fujii, Kentaro Miyoshi, et al. A Case of Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension. Internal medicine (Tokyo, Japan). 2024
Kiichiro Ninomiya, Daisuke Ennishi, Kunio Okamoto, Midori Ando, Satoko Nakamura, Shuta Tomida, Yoshiyuki Ayada, Go Makimoto, Eiki Ichihara, Natsuko Okita, et al. Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report. JCO precision oncology. 2024. 8. e2400228